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Purpose: The objective was to determine whether optically stimulated luminescent
dosimeters (OSLDs) were appropriate for in vivo measurements in high dose rate
brachytherapy. In order to make this distinction, three dosimetric characteristics were
tested: dose linearity, dose rate dependence, and angular dependence.The Landauer nan-
oDot™ OSLDs were chosen due to their popularity and their availability commercially.
Methods: To test the dose linearity, each OSLD was placed at a constant location and
the dwell time was varied. Next, in order to test the dose rate dependence, each OSLD
was placed at different OLSD-to-source distances and the dwell time was held constant. A
curved geometry was created using a circular Accuboost® applicator in order to test angu-
lar dependence. Results: The OSLD response remained linear for high doses and was
independent of dose rate. For doses up to 600 cGy, the linear coefficient of determination
was 0.9988 with a response of 725 counts per cGy. The angular dependence was signif-
icant only in “edge-on” scenarios. Conclusion: OSLDs are conveniently read out using
commercially available readers. OSLDs can be re-read and serve as a permanent record
for clinical records or be annealed using conventional fluorescent light. Lastly, OSLDs are
produced commercially for $5 each. Due to these convenient features, in conjunction with
the dosimetric performance, OSLDs should be considered a clinically feasible and attractive
tool for in vivo HDR brachytherapy measurements.
Keywords: Accuboost, brachytherapy, dosimetry, high dose rate brachytherapy, iridium 192, kilovoltage dosimetry,
nanodot, optically stimulated luminescent detectors
INTRODUCTION
Optically stimulated luminescence (OSL) is light emission from
previously irradiated crystalline materials when stimulated by a
light of different wavelength. OSL has been employed for film
dosimetry (Schembri and Heijmen, 2007), computed tomography
(CT) dosimetry (Yukihara et al., 2009; Ruan et al., 2010), per-
sonal dosimetry monitoring (Akselrod et al., 1999; Lee and Lee,
2001; Yukihara and McKeever, 2008), and space dosimetry (McK-
eever, 2002). In OSL materials, crystal-lattice imperfections are
introduced to trap electrons, which are liberated by ionizing radi-
ation (Akselrod et al., 1990; Akselrod et al., 1999; Yukihara and
McKeever, 2008).
The materials used for OSL are essentially the same as the
more well-known thermoluminescent dosimeters (TLDs), how-
ever optically stimulated luminescent dosimeters (OSLDs) are
stimulated using light while TLDs are stimulated using heat (McK-
eever and Moscovitch, 2003). The most common OSL dosime-
ter material – carbon-doped aluminum oxide (Al2O3:C) – was
originally introduced as a TLD (Akselrod et al., 1990; Yukihara
and McKeever, 2008). As an OSLD, aluminum oxide is capable
of detecting absorbed dose greater than 105 Gy, with negligible
temperature dependence.
There have been varying results regarding angular depen-
dence, which depend on the irradiation environment. Specifically,
Jursinic (2010) has measured negligible angular dependence. On
the other hand, Kim et al. (2011) measured a response which was
72% higher at an oblique angle than the response when the inci-
dent beam was en face to the OSLD. Kerns et al. (2011) measured
a milder effect of only 4% lower response in oblique angles vs. en
face beam.
Optically stimulated luminescent dosimeters are commonly
housed in a plastic container around 100–200 mm3. The small size
allows placement in cramped spaces which suffer from acute radia-
tion toxicity such as an inframammary fold or between labia. Using
physical measurements overcomes the inherent computational
challenges of accounting for day-to-day variations, especially in
deformable organs such as the breast.
The performance of OSLDs has been well-documented in the
megavoltage regime and in the kilovoltage range (Akselrod et al.,
1990; Akselrod et al., 1999; Lee and Lee, 2001; McKeever, 2002;
McKeever and Moscovitch, 2003; Jursinic, 2007; Schembri and
Heijmen, 2007; Yukihara and McKeever, 2008; Reft, 2009; Yukihara
et al., 2009; Ruan et al., 2010; Benevides et al., 2011; Kerns et al.,
2011; Kim et al., 2011). However, the ability of OSLDs to measure
dose in the kilovoltage regime of HDR brachytherapy has not been
demonstrated. Furthermore, the OSLD physical sensitive volume
must be shown to resolve the high gradients ubiquitous to HDR
(Dewerd et al., 2009). This investigation characterized general
dosimetric properties of an OSLD in HDR brachytherapy using an
Ir-192 source. In addition to quantifying dose linearity and dose
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rate dependence, a novel method is introduced to measure angular
dependence of an OSLD.
MATERIALS AND METHODS
The OSLDs used for this study were a batch of InLight/OSL
nanoDot™ (Landauer, Inc., Glenwood, IL, USA) dosimeters. The
OSLDs are circular disks with a 5-mm diameter and 0.2 mm
thick made of carbon-doped aluminum oxide with a 0.05-mm
thick polyester-film cover layer. The disks are housed within a
10 mm× 10 mm× 2 mm light-tight plastic holder. Two OSLDs
are shown in Figure 1 below to illustrate the open and closed
positions. The manufacturer-specified housing wall-thickness is
0.36 mm and has a density of 1.03 g/cm3.
Optically stimulated luminescent dosimeters signals can be
read out multiple times. Therefore, for each count measurement,
each OSLD was read out 7–10 times in order to reduce statisti-
cal noise. A correction factor was applied to account for the read
depletion of 0.4% observed by Jursinic (2007). OSLDs were given
16–24 h after irradiation to stabilize (Jursinic, 2007; Reft, 2009;
Jursinic, 2010; Kerns et al., 2011; Kim et al., 2011). OSLDs were
reused by optically bleaching OSLDs for 24–72 h using a fluores-
cent lamp (Yukihara et al., 2005; Yukihara and McKeever, 2008;
Reft, 2009; Jursinic, 2010).
The brachytherapy source was an Ir-192 seed (half-life: 74 days,
average 380 keV emitted energy) with an initial activity around
10,000 mCi (Khan, 2003). Over the course of this investigation, the
activity varied between 6,000 and 10,000 mCi as specified by Amer-
ican Association of Physicists in Medicine (AAPM) Task Group
(TG) 43 and AAPM TG-56, respectively (Nath et al., 1997; Rivard
et al., 2004).
DOSE AND DOSE RATE DEPENDENCE
Figure 2 shows the set-up used to test dose linearity and dose rate
dependence. The pink oval represents the HDR source while the
blue rectangles represent possible OSLD measurement positions.
The OSLD’s embossed “Landauer” text was perpendicular to the
block and facing toward the catheter.
In order to determine the dose dependence, an OSLD was
placed in location B and the dwell time was varied. The distance
between source and OSLD remained constant to maintain con-
stant dose rate. On the other hand, in order to test the dose rate
dependence, the dwell time was held constant and the OSLD was
placed in one of the four different locations. By the inverse-square
law, different OSLD-to-source produced varying dose rates.
FIGURE 1 |Two nanoDot™ OSLDs shown to simultaneously display
closed (left) and open (right) positions.
By placing the device perpendicular to the scan axis, a CT
scan of the dose rate measurement device was used to give sub-
millimeter resolution measurements of exact OSLD locations.
The OSLD locations are 1.88, 2.85, 3.88, 4.92, 5.87, 6.88, 7.86,
8.89, and 9.83 cm from the source. The CT dataset was imported
into the HDR treatment planning software, Oncentra version 4.0
(Nucletron B.V., Veenendaal, Netherlands).
The exact position of the HDR Ir-192 source within the catheter
itself was localized using radiochromic (GAFCHROMIC, Ash-
land, Covington, KY, USA) film. This resulted in a 2 mm shift,
which is reasonable given the Ir-192 source schematics described
by Daskalov et al. (1998).
ANGULAR DEPENDENCE
A circular AccuBoost® (Advanced Radiation Therapy, LLC., Tyngs-
boro, MA, USA) applicator was chosen to provide a rigid circular
shape for angular dependence measurements. AccuBoost® pro-
cedures use an HDR Ir-192 source in this applicator to deliver
radiation to breast lesions (Rivard et al., 2009). To minimize the
anisotropy of an HDR source, the applicator positions the source’s
long axis normal to the applicator’s central axis (Nath et al., 1995,
1997). The applicator has been shown to be large enough for a
high dose rate, yet small enough to approximate as a point source.
Figure 3 shows the applicator’s dimensions alongside the OSLD’s
(dark blue rectangle) – and four dwell locations (purple blocks).
The applicator diameter was measured to be 69.7 mm. A Monte
Carlo study by Rivard et al. (2009) modeled the AccuBoost® source
as a cylinder 0.65 mm in diameter and 3.6 mm long. The 70 mm
applicator is approximately one order larger than the source
(3.6 mm); therefore, the seed was approximated as a point source.
This assertion will be discussed later.
RESULTS
DOSE LINEARITY
This geometry corresponds to Figure 2 where measurements were
made at location B and the source-to-detector distance remained
constant. Figure 4 shows doses from 0 to approximately 200 cGy
where the relationship between counts and dose has been previ-
ously shown to be linear (Kerns et al., 2011; Kim et al., 2011). This
investigation yielded similar results: a linear regression modeled
the relationship up to 200 cGy with a coefficient of determination
(R2) of 0.9997 and a slope of 600 counts/cGy. The coefficient of
variation of the individual OSLD measurements was below 0.02
for each OSLD used.
Previous studies have simply stated that OSLDs possess a supra-
linear relationship between dose and counts above 200 cGy (Kerns
FIGURE 2 | Dose rate measurement schematic.
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et al., 2011; Kim et al., 2011). However, HDR brachytherapy entails
a larger doses up to around 500 cGy. Therefore, this investiga-
tion measured a second region up to 600 cGy. Figure 4 shows the
results for a linear fit to measurements up to 600 cGy alongside the
200 cGy linear fit presented earlier in Figure 4. A linear regression
fit to 600 cGy had a slightly lower R2 of 0.9988 and a larger slope
of 725 counts/cGy.
FIGURE 3 | Angular dependence test using circular Accuboost®
applicator.
FIGURE 4 | Counts vs. dose, using a constant dose rate, for a larger
total dose.
The lower limit of dose linearity was not investigated because
HDR delivers such large doses expected in most HDR brachyther-
apy applications (Nath et al., 1997). However, the lowest dose
measured at 20 cGy remained in the linear fit for both 200 and
600 cGy thresholds; also, extrapolating to background count lev-
els (200 counts) corresponded to 0.3 cGy. Regardless, low dose
levels are problematic to deliver because of the short dwell
times: a more rigorous timer accuracy would be required than
the 2% guideline established by Nath et al. (1997). Secondly,
there is significant relative contribution due to the finite transit
time.
The authors note that there may be better models for the OSLD
response. However, the linear model fit with an R2 larger than
0.99. Clinically, a linear model was preferred because it requires
only a single fitted parameter.
DOSE RATE DEPENDENCE
This geometry corresponds to Figure 2 where measurements
were made at locations A through D. Different dose rates were
obtained as dictated by the inverse-square law. A 250 s dwell
time was required to deliver 100 cGy to the OSLD placed at
the nominal 5 cm position. Figure 5 demonstrates the OSLD’s
independence to dose rate by showing the relationship between
OSLD response and the dose rate, with overall R2 of 0.999.
Measurements agreed well with the theoretical dose as calcu-
lated using TG-43 and inverse-square factor calculated using the
positions summarized previously in Section II.A, with a maxi-
mum error of 3.9% relative to the measurements (Nath et al.,
1995). The computational output factors calculated by Oncen-
tra agreed well, with a maximum error of 2.3% relative to the
measurements.
FIGURE 5 | Relationship between counts and dose, using different
dose rates.
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ANGULAR DEPENDENCE
Measurements by the Nucletron Source Position Simulator tool
showed the source traveled 211.0 mm. Using the previously mea-
sured diameter of 69.7 mm and the catheter radius of 1 mm in,
the source would travel 212.6 mm for a full rotation. However, the
end of the catheter was sealed and the applicator needed to have
some sort of entry point – thereby traversing only 356˚ out of
360˚. Instead of 212.6 mm, the source will travel 210.2 mm from
the beginning to end of the applicator. The ratio between angle
and the source travel distance was determined to be 1.7˚/mm. The
position-to-angle ratio was tested by using a laser to examine the
coincidence of the 0˚and 180˚ dwell positions within the applica-
tor. Future simulations should model the source as a torus with a
67.7 mm major diameter and 0.3 mm minor diameter over only
356˚ out of 360˚.
The dependence for both azimuthal and transverse angular
planes is shown in Figure 6. There was a slight angular depen-
dence most noticeable near 0˚ and 180˚ – representing an“edge-on”
irradiation – where response dropped up to 20%. However, at an
incident angle of 30˚ the drop in response is only 10%. The slight
asymmetry of Figure 6 will be addressed in the discussion section.
The response taken as a function of the sine of the angle yielded
an acceptable linear fit, with an R2 of 0.858. This model is shown
in Figure 7 for the theta plane.
DISCUSSION
Using physical measurements avoids potential pitfalls found in
Monte Carlo modeling of HDR such as source construction, mov-
able components, source emission, and source activity distribution
(Dewerd et al., 2009). Physical measurement accuracy was most
dependent upon volume averaging, self-attenuation, and absorbed
dose sensitivity (Dewerd et al., 2009). In particular, OSLDs can
avoid volume averaging issues by placing the face orthogonal to
the anticipated gradient, thus giving resolution of 0.2 mm – the
width of the disk.
DOSE DEPENDENCE
This investigation also observed linearity in the kilovoltage HDR
energy regime with for doses up to 600 cGy. The observed linear-
supralinear behavior between the 200 and 600 cGy thresholds is
attributed to a residual radiation-induced signal due to the filling
FIGURE 6 | Angular dependence of OSLD.
of deeper traps in the detector (Jursinic, 2010). The focus of this
investigation was not to establish an absolute calibration factor
per se, but to investigate the fit of a linear model for OSLDs in the
kilovoltage energy range. In principle, with two measurements,
a linear model could be extrapolated to completely characterize
response up to 600 cGy.
DOSE RATE DEPENDENCE
Previous OSLD studies have been conducted on linear accelerators
where dose rate is determined by the pulse rate. In other words,
the dose rate per unit second is varied, but the “instantaneous
dose” – dose per pulse – does not change (Khan, 2003). In this
investigation, the instantaneous dose rate was changed through
variation of the source-to-detector distance and the relationship
between counts and dose rate was found to be linear. Table 1 shows
the dose calculated through either TG-43 calculations or Oncentra
calculations is consistent with measured results, with a maximum
discrepancy of 3.9%, which is still below the clinically acceptable
threshold of 5% (Nath et al., 1995; Khan, 2003; Klein et al., 2009).
ANGULAR DEPENDENCE
The angular dependence of the system appears to be asymmetric.
The most probable, explanation for the asymmetry is the position-
ing of the OSL material within its casing. Specifically, the OSLD
was positioned at the center of the applicator. As can be inferred
from Figure 1, the center of the sensitive disk is actually not coin-
cident with the center of casing – in fact, the two centers were
approximately 1.5 mm apart in both lateral dimensions. The OSL
material is located behind inscribed cross-hairs which can be seen
in the left side of Figure 1, immediately below the sticker. In order
to better reflect a clinical set-up, the OSLD was positioned relative
to the plastic casing rather than the sensitive OSL material. Again,
FIGURE 7 | Angular dependence fitted to sin(θ).
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Table 1 | Dose rate comparison between measurement vs. theoretical calculations and Oncentra calculations.
Nominal position Avg counts measured Avg counts normalized Inverse-square % Diff (Inv sq) Oncentra calculation % Diff (Oncentra)
5 72388.3 1.000 1.000 – 1.000 –
6 50908.5 0.703 0.703 0.0 0.710 0.9
7 38428.3 0.531 0.511 3.9 0.519 2.3
8 28443.3 0.393 0.392 0.2 0.389 1.0
this set-up was purposely chosen to represent the scenario which
would be implemented for clinical practice. Ideally, the angular
dependence would not be relevant because the irradiation would
be immediately en face to the OSLD.
The next reason for the asymmetric angular dependence would
be the approximation of the Ir-192 seed as a point source. For
the angular dependence tests within the Accuboost applicator, the
OSLD-to-source distance was 35 mm. The actual OSLD mater-
ial is a 2-mm disk. Therefore, the OSLD-to-source distance was
approximately one order of magnitude larger than the detector.
Strictly speaking, the Ir-192 seed is small line source with the
OSLD off-center and closer to one side of the Accuboost appli-
cator. Comparing the effective pathlengths using a point source
approximation and a perfectly centered OSLD leads to a maximum
uncertainty of 4.4%, with a mean uncertainty of approximately
1.8%.
The last reason for the asymmetric angular dependence would
be the elastic stiffness of the HDR source: by definition, any cable
which traverses 90˚ will be tangential to a wall at least once. This
contact is dictated by the radius of curvature. This could lead to
the source not positioned as expected in terms of both orientation
and location, which would lead to an uncertainty of approximately
0.5 mm in a radial direction.
Figure 7 shows the linear relationship between the response
and the sine of the θ angle. The coefficient of determina-
tion was 0.858. Additionally, the linear model was within the
error bars for 20 out of 21 measurements. The maximum
loss of response was observed in only an “edge-on” scenario.
This investigation recommends maintaining an incident angle
greater than 30˚ – where there is only a 10% drop in response.
An angular correction factor could theoretically be determined
from Figure 7, especially if an edge-on scenario was clinically
unavoidable.
CLINICAL RELEVANCE AND ANTICIPATED LIMITS
TLDs vs. OSLDs
Both TLD and OSLD measurements are based upon materials
measure the amount of visible light emitted from the mater-
ial after exposure to ionizing radiation. While TLDs have been
historically used for clinical in vivo dosimetry measurements for
many years, many clinics have replaced TLDs with OSLDs (Low
et al., 2011). In fact, OSLDs have become so predominant that the
Radiological Physics Center (RPC), the governing institution for
credentialing clinical radiotherapy units changed in 2010 from
TLDs, in use since 1968, to OSLDs for annual output checks
(Low et al., 2011). OSLD measurements are available in less
time and faster than with TLDs (Yukihara et al., 2005; Mayles
et al., 2007). McKeever and Moscovitch (2003) have written a
comprehensive article which examines OSLDs in comparison with
TLDs.
In order to be properly read, TLDs require about 24 h for
stabilization and can only be read once (Akselrod et al., 1990).
Additionally, due to their delicate construction, TLDs are difficult
to handle and the process of read out is extremely time consum-
ing (Yukihara and McKeever, 2008). For example, TLDs require
vacuum tweezers, scales, nitrogen, and annealing ovens (Yuki-
hara and McKeever, 2008). Additionally, the clinic must employ
control TLDs and glow curves which are unique to each set of
measurements (Akselrod et al., 1990).
Optically stimulated luminescent dosimeters are read out using
light, which is much faster, more precise, and, in general, more
reproducible than heating, as used by TLDs (Yukihara et al., 2005).
Additionally, OSLD dose curves are established by the vendor prior
to shipping which precludes establishing a control set of OSLDs
for every batch (McKeever, 2002). Accounting for read deple-
tion, OSLDs can be re-read and there are currently clinics which
store OSLDs used to establish a permanent record (McKeever,
2002).
OSLD clinical advantages
As previously discussed, OSLDs provide significant time-savings
for the medical physicist, however these detectors also provide
a superb detector choice for physicians. For example, due to
their thin disk size, OSLDs can be placed in inframammary fold
or between labia, which are common sites of significant acute
radiation toxicity. These regions frequently possess high dose gra-
dients and with careful placement, OSLDs can be used without
noticeable volume averaging effects. Specifically, OSLDs should
be placed with its face normal to the direction of the dose gra-
dient. And, finally, angular dependence appears to be noteworthy
only in “edge-on” scenarios, which can be avoided in most clinical
situations.
HDR brachytherapy is used at this particular institution for a
wide range of treatment techniques including tandem and ovoid
treatments for cervical cancer, balloon brachytherapy for accel-
erated partial breast irradiation (APBI), intrabronchial insertions
for constrictive upper airway disease, Freiburg flap applications
for superficial cancers, and wide range of interstitial applications.
This institution prefers to use Accuboost® for the boost doses in
breast cases to overcome issues of deformable breast volume (Oh
et al., 2006;Yang and Rivard, 2009). Hence, the circular Accuboost®
applicators were available.
While calculated dose to the targeted tissue is reliable, the dose
to other organs such as skin is not trivial. Dose to the skin sur-
face is of significant consequence as acute toxicity may lead to
treatment breaks and if severe may also lead to consequential
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late effects such as telangectasias and subcutaneous fibrosis, as
sometimes found in APBI (Yang and Rivard, 2010). The large
majority of HDR brachytherapy doses are prescribed around 300–
500 cGy per fraction. APBI prescription and skin dose are 340
and 495 cGy, respectively (Yang and Rivard, 2010). In the future,
if anticipated doses delivered will be higher, measurements can
determine whether the behavior is linear past 600 cGy. As seen in
dose rate measurements, these OSLDs showed the ability to han-
dle the high dose rates even at 5 cm, in air. In a clinical case, there
would also be soft tissue attenuation reducing the dose rate.
CONCLUSION
This work is the first investigation of the use of OSLDs explicitly
using HDR sources: testing dose linearity, dose rate capabilities,
and angular response. The OSLDs have been shown to overcome
unique challenges of HDR brachytherapy, namely high dose gra-
dients and high dose rate. With regards to the high dose gradients,
due to its physical dimensions, the OSLDs is able to resolve gradi-
ents as thin as 0.2 mm. Also, due to their small size, OSLDs avoids
the pitfalls of many HDR brachytherapy detectors such as volume
averaging and limited spatial resolution.
This investigation did not focus on measuring an absolute cali-
bration factor, but instead established the linearity of OSLDs up to
600 cGy. In other words, for the majority of clinical applications,
linear interpolation is appropriate. The OSLDs have been shown
to perform with a linear response at high dose rates in air. There
was an angular dependence observed which became significant
in “edge-on” scenarios where the radiation source was directly
incident upon the edge of the OSLD. This was attributed to the
purposeful shift in order to align the center relative to the OSLD
casing rather than the OSL sensitive material. Regardless, it is rec-
ommended that the angle of incidence remains larger than 30˚,
but it is possible to derive an angular correction factor if oblique
angles are unavoidable using a linear model between response and
the sine of the incident angle.
Patient positioning can vary significantly day-to-day, making
accurate computational modeling of all tissues at risk quite dif-
ficult, especially those not immediately adjacent to the treated
tissue. Using physical measurements is a practical solution because
OSLDs are small and provide an almost“point”detector geometry.
While TLDs have been historically used for many years, recently
many clinics have recognized the convenience and reliability of
OSLDs and replaced TLDs. Specifically, the RPC, the governing
institution for credentialing clinical radiotherapy units changed
in 2010 from TLDs, in use since 1968, to OSLDs for annual output
checks.
Optically stimulated luminescent dosimeters have an advantage
in their convenient and time-saving read out; afterward, they can
be re-read, serve as a permanent record, or reused by annealing
with conventional fluorescent light. Additionally, OSLDs are com-
mercially available – in bulk if necessary – for around $5 each. For
these reasons, combined with their dosimetric performance shown
in this investigation, OSLDs should be considered a feasible and
attractive tool for in vivo HDR brachytherapy measurements.
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